Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01578499 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
A Phase 3 study, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 131
- Enrollment target
NCT01578499 is a Phase 3 study that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 131 participants.
The verdict
NCT01578499, a Phase 3 study, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 131 participants
- Enrollment target
Study Summary
The purpose of this study is to determine objective response rate (ORR), lasting at least 4 months (ORR4), with brentuximab vedotin in participants with cluster of differentiation antigen 30 positive (CD30+) cutaneous T-cell lymphoma \[mycosis fungoides (MF) and primary cutaneous anaplastic large cell lymphoma (pcALCL) \]compared to that achieved with therapy in the control arm.
Interventions
- DRUG Brentuximab Vedotin
- DRUG Methotrexate
- DRUG Bexarotene
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2012-06-11 |
| Est. Completion | 2018-07-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01578499
The ClinicalTrials.gov registry entry for NCT01578499 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Millennium Pharmaceuticals, which has 135 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Brentuximab Vedotin is the first listed.
NCT01578499 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01578499 about?
NCT01578499 is a clinical study titled "A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)". The purpose of this study is to determine objective response rate (ORR), lasting at least 4 months (ORR4), with brentuximab vedotin in participants with cluster of differentiation antigen 30 positive (CD30+) cutaneous T-cell lymphoma \[mycosis fungoides (MF) and primary cutaneous anaplastic large ce...
What is the current status of trial NCT01578499?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 131 participants. The study started on 2012-06-11. Estimated completion is 2018-07-06.
What interventions are being tested in trial NCT01578499?
The interventions under investigation include: Brentuximab Vedotin (DRUG), Methotrexate (DRUG), Bexarotene (DRUG).
Who is sponsoring clinical trial NCT01578499?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.